Cancer Drug Prices Inconsistent With Value Scores From NCCN Prescribing Tool
Executive Summary
Research presented at the American Society for Clinical Oncology annual meeting evaluates cancer drug costs and benefits using two value frameworks meant to assist physicians and patients in treatment decisions.
You may also be interested in...
ASCO Cancer Drug Valuation Tool Will Incorporate Patient Preferences
Software that physicians and patients could use to inform value assessments for cancer drugs could be available within a year.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.